BACKGROUND: In the face of availability of newer @entity734 ( @entity734 ) such as @entity2812 and @entity1771 , there is need to reassess the role of older @entity734 in the treatment of @entity3149 ( @entity3149 ). OBJECTIVES: To explore whether @entity2812 and @entity1771 monotherapy or polytherapy can be effective options in the treatment of @entity3149 , and to determine whether older @entity734 , such as @entity3174 and @entity2049 , have a role in the treatment of @entity3149 . DESIGN: A retrospective cohort study. SETTING: A large academic teaching hospital. @entity1 : Seventy-two consecutive @entity3149 @entity1 treated with @entity1092 , @entity2812 , @entity1771 , @entity3174 , or @entity2049 between April 1, 1991, and March 31, 2001. METHODS: We compared the efficacy of @entity1092 , @entity2812 , and @entity1771 monotherapy or polytherapy in the control of different @entity410 types of @entity3149 , and compared their efficacy and tolerability with the efficacy and tolerability of @entity3174 and @entity2049 . RESULTS: @entity410 outcome did not differ when @entity1 receiving @entity1092 monotherapy (n = 36) were compared with those receiving @entity2812 monotherapy (n = 14), and when @entity1 receiving @entity1092 polytherapy (n = 22) were compared with those receiving @entity2812 polytherapy (n = 21) or @entity1771 polytherapy (n = 15) (P>.05 for all). The combined data of @entity410 control by all 3 @entity734 were poorer when compared with the combined data of generalized tonic-clonic @entity410 control by all 3 @entity734 (P =.03), but not when compared with the combined data of @entity2048 control by all 3 @entity734 (P =.43). @entity1092 , @entity2812 , and @entity1771 , when compared with @entity3174 or @entity2049 , demonstrated significantly better control of @entity410 (P<.01 for all), but not of generalized @entity410 (P>.11 for all). CONCLUSIONS: @entity2812 and @entity1771 are effective alternative options to @entity1092 in the treatment of @entity3149 . @entity2812 is an effective option as monotherapy and polytherapy. @entity1771 is an effective option as polytherapy, but more data are needed to determine if it is an effective option as monotherapy. More effective therapy is needed to improve @entity410 control. Older @entity734 , such as @entity3174 and @entity2049 , may not be indicated in @entity3149 @entity1 .

Evolving antiepileptic drug treatment in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'myoclonic seizure', 'Seizure', 'tonic-clonic seizures', 'myoclonic seizures'] @entity1092 :: ('MESH:D014635', 'Chemical') :: ['Valproic acid', 'valproic acid'] @entity2049 :: ('MESH:D002220', 'Chemical') :: ['carbamazepine'] @entity1771 :: ('MESH:C052342', 'Chemical') :: ['Topiramate', 'topiramate'] @entity3174 :: ('MESH:D010672', 'Chemical') :: ['phenytoin'] @entity3149 :: ('MESH:D020190', 'Disease') :: ['juvenile myoclonic epilepsy', 'JME'] @entity2048 :: ('MESH:D004832', 'Disease') :: ['absence seizure'] @entity2812 :: ('MESH:C047781', 'Chemical') :: ['Lamotrigine', 'lamotrigine'] @entity734 :: ('MESH:D019966', 'Disease') :: ['AEDs', 'antiepileptic drugs']
@entity3149 :: (MESH:D020190,Disease) :: ['juvenile myoclonic epilepsy']
